Abstract 145P
Background
Macrophages exert their functions mainly through SIRPa receptor, which interacts with CD47 on cellular targets. As many cancer cells overexpress CD47 to evade immune surveillance, blocking SIRPa-CD47 interaction represents a promising approach to control tumor progression. The clinical progress of anti-CD47 antibodies were hindered by either side effects or lacking appreciable efficacy. To overcome this dilemma, we engineered a SIRPa-fusion protein that exhibits superior efficacy against multiple tumor types while maintaining good safety profiles.
Methods
Using structure-guided protein engineering, we selected a SIRPa mutant that exhibited marked phagocytic abilities against tumors while maintaining good safety features on normal cells. To assess the efficacy of this molecule, it was tested in multiple xenograft mouse models alongside competing biologics currently in clinical trials. We also performed quantitative RNA transcriptional analysis to evaluate the changes in gene expression inside tumor and in the tumor microenvironment.
Results
Comparing to other clinical candidates, HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells. We have analyzed 14 human tumor xenograft models, HCB101 consistently showed excellent efficacy against heme and solid tumors, with tumor growth inhibition index ranging from 60-100% at the dose of 0.5-10mg/kg over placebo. We also observed an increase in M1/M2 macrophage ratio after the treatment with HCB101, which correlated with the observed anti-tumor efficacy. Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression comparing to other competing molecules. This suggested a unique MOA underlying HCB101’s superior efficacy. There was no apparent adverse reaction observed during the toxicology studies, indicating a good safety profile.
Conclusions
Comparing to relevant clinical candidates, HCB101 exhibits superior efficacy in 14 different CDX models of hemotological and solid tumors while maintaining good safety profiles. It is a highly effective biologic with robust efficacy, both as monotherapy and in combination. Clinical trial of HCB101 is now in progress.
Clinical trial identification
NCT05892718.
Legal entity responsible for the study
HanchorBio, Inc.
Funding
HanchorBio, Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display